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Abstract
Background: Although meningioma is a common disease, there is a lack of understanding of the underlying
molecular mechanisms behind its initiation and progression. We used combined miRNA-mRNA transcriptome
analysis to discover dysregulated genes and networks in meningiomas.
Methods: Fourteen fresh-frozen meningioma samples and one human meningeal cell line were analyzed by using
miRNA and whole transcriptome microarray chips. Data was filtered and analyzed. Candidate miRNAs and mRNAs
were selected for validation in fifty-eight patient samples. miRNA and target mRNA relationships were assessed by
inhibiting miRNA in meningioma cells. Apoptosis and viability assays were also used as functional tests.
Results: With the whole transcriptome microarray, 3753 genes were found to be dysregulated, and 891 miRNAs
were found to be dysregulated as a result of miRNA microarray. Results were combined and analyzed with
bioinformatics tools. Top differential pathways included those of inflammation, cancer, and cellular growth and
survival. The oncosupressor PTX3 was constitutively low in meningioma samples. Moreover, PTX3 negatively
correlated with miR-29c in our samples. Inhibiting miR-29c upregulated the PTX3 level, induced apoptosis of
meningioma cells, and decreased cell viability. CABIN1, miR-29c, TMOD1, PTX3, RPL22, SPARCL1 and RELA were
correlated with clinicopathological features in patient samples.
Conclusions: Our results present the first integrated mRNA-miRNA analysis in meningiomas. miR-29c-3p and PTX3
are inversely correlated in tissues and meningioma cells, hinting that PTX3 can be regulated by miR-29c-3p.
Furthermore, we determined potential clinicopathological markers.
Keywords: meningioma, microarray, miRNA, transcriptome, PTX3, miR-29c
Background
Meningiomas account for 30% of primary brain tumors
and occur at a rate of 5 per 100,000 individuals [1]. They
originate from cap cells of the arachnoidal membrane
[2], and the peak age for occurrence is the seventh
decade of life [3]. Meningiomas are generally benign but
malignant meningiomas have a high tendency to recur.
First choice of treatment is surgery, and predictive bio-
markers for meningioma progression that could guide
oncologists for treatment alternatives are insufficient.
Although meningiomas are common, there is a lack of
understanding of underlying molecular mechanisms be-
hind their initiation and progression. To elucidate some
of these mechanisms, we used combined miRNA-mRNA
transcriptome analysis to discover novel genes and net-
works in meningiomas. 14 fresh-frozen meningioma
samples were used to integrate miRNA and mRNA
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microarray analysis. Herein, we describe integrated ana-
lysis of gene networks that might play an important role
in the initiation and progression of meningiomas, with




Fifty-eight fresh samples of meningioma tumor tissue
(45 WHO grade 1 and 12 WHO grade 2 and 1 WHO
grade 3), acquired from surgery, were immediately trans-
ported to the cell culture facility for processing as de-
scribed below. A portion of these fresh-frozen tissues
were used for microarray analysis. Clinical information
was collected for each sample, including demographic
data, tumor location, treatment options, and prognosis.
Cell cultures
For monolayer culture, two fresh meningioma tissue
samples (named as MEN-117 and MEN-141) were
minced and grown in culture medium (Dulbecco’s
Modified Eagle Medium, Gibco) with 10% fetal bovine
serum and 1% antibiotics (streptomycin and penicillin)
and incubated at 37 °C in a humidified atmosphere (5%
CO2). To prevent loss of character, miRNA transfections
of primary cell cultures were done at passage 2. Human
meningeal cells (Cat. #1400, ScienCell Laboratories,
Carlsbad, California) were cultured according to the pro-
vider’s protocol and used as the healthy control.
Microarray analysis
Tumor tissues were ground with liquid nitrogen, and TRI-
zol (ThermoFisher Scientific) was added according to the
manufacturer’s protocol for total RNA isolation. Whole
transcriptome expression profiling was done using Affy-
metrix Human Gene 2.1 ST Array Strip (Cat no: 902,114,
Affymetrix, Santa Clara, CA), which contains over 47,000
transcripts. miRNA microarray analysis was done with the
Affymetrix miRNA 4.1 Array Strip (Cat no: 902,404). The
chips were used in the GeneAtlas system and the resulting
data was analyzed with Transcriptome Analysis Console
(TAC) 3 software (Affymetrix).
miRNA and mRNA expression levels
The expression levels of selected miRNAs in patient
samples, meningeal cells, and primary cells grown as a
monolayer after anti-miRNA transfection were evaluated
with real-time polymerase chain reaction (PCR) using
miRNA primers obtained from Exiqon (Vedbæk,
Denmark). First, cDNA was synthesized from all miRNA
samples according to the manufacturer’s protocol (Exi-
qon, Cat. No.: 203,300). Synthesized cDNAs were used
as templates for gene-expression analysis through real-
time PCR, while mRNA levels were measured using
Taqman primers (ThermoFisher) after cDNA synthesis.
Data was analyzed with the 2-ΔΔCt method. For miRNA
normalization, 5S RNA was used. For mRNA
normalization, GAPDH was used.
Optimiziation of anti-miRNA transfection
Cy3 Dye-Labeled Pre-miR Negative Control #1 (Cat:
AM17011, ThermoFisher) was used to evaluate the abil-
ity of X-tremeGENE siRNA Transfection Reagent
(Roche, Cat. No.: 04476093001) to transfect primary
meningioma cells under the fluorescent microscope.
After validation, anti-miRNA mimics (Ambion Pre-miR
miRNA Precursors PM: 114,065) were transfected into
cells. To determine the intracellular functionality of
anti-miRs, total RNA isolation and miRNA reverse tran-
scription was done and followed by real-time PCR. The
targeted miRNA levels were measured 48 h after trans-
fection. The control groups were the X-tremeGENE
group, in which only the transfection reagent and
medium were delivered to cells, the scrambled miRNA
group (Ambion anti-miR miRNA mimics), and the nega-
tive control group, which contained only medium.
Annexin V staining and viability assay
To elucidate the apoptotic effects of hsa-miR-29c-3p
and its target PTX3 on primary meningioma cells,
annexin V and 7-AAD staining was performed by using
apoptosis detection kit I (BD Pharmingen, San Diego,
California) 72 h after transfection of anti-miR-29c-3p.
Staining was carried out according to the manufacturer’s
protocol by using BD FACSAria III cell sorter (BD
Biosciences).
Cell viability after anti-miR-29c transfection was
assessed at day 3 and day 4 with CellTiter 96 Aqueous
One Solution Cell Proliferation Assay (MTS) (Promega,
Madison, Wisconsin) according to the manufacturer’s
protocol. Scrambled anti-miR was used as a control. Re-
sults were obtained by detecting absorbance at a wave-
length of 490 nm with the Elisa microplate reader
(BioTek, Winooski, Vermont).
Statistical analysis
The one-way between-subjects ANOVA (unpaired)
method was used to evaluate the microarray results.
Real-time PCR data was analyzed by using the 2-ΔΔCt
method. Spearman’s two-tailed correlation test was used
to determine correlations of tumor size and mRNA-
miRNA levels, and miRNA and mRNA target levels. For
other clinicopathological correlations, the two-tailed chi-
square test was used. The calculation and interpretation
of p values for functions and gene networks (Table 1)
was done with a right-tailed Fisher’s exact test. All other
statistical analyses were done using student’s t-test. Dif-
ferences with p values of less than 0.05 were considered
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statistically significant. The high and low miRNA or
gene groups of patients were separated according to the
median expression level value. Significant outliers were
evaluated for each experiment and removed from
analysis.
Results
Differential expression of miRNAs and mRNAs in
meningioma
Fourteen meningioma samples and one healthy human
meningeal cell line were used to profile miRNA and
gene expression (Additional file 1: Table S1). Of 48,226
genes that were checked for expression, 1257 genes were
found to be upregulated and 2496 were found to be
downregulated as a result of whole transcriptome micro-
array (Additional file 2: Figure S1). As a result of miRNA
microarray, of 6631 miRNAs checked, 580 genes were
found to be upregulated and 311 were found to be
downregulated (Additional file 3: Figure S2). The results
from both microarrays were combined and analyzed by
using TAC (Affymetrix), DAVID, KEGG and Reactome
software. To increase confidence, fold change (linear) of
less than −4 or fold change (linear) greater than 4 and
the ANOVA p value (condition pair) less than 0.01 were
chosen as selection criteria in both arrays. Deregulated
miRNAs and mRNAs were analyzed for their collective ef-
fect on important molecular and cellular events (Table 1).
Candidate mRNAs and miRNAs were chosen according
to pathways and networks relevant to meningioma, as well
as well-matched expression levels of miRNAs and their
potential mRNA targets, with the help of web-based
databases (mirdb.org/miRDB/, mirtarbase.mbc.nctu.edu.tw,
http://targetscan.org/, pictar.mdc-berlin.de, http://www.mi-
crorna.org/). The predicted targets were chosen to balance
prediction match scores and the relevancy and novelty of
the genes in meningioma research (Table 2). The data
discussed in this publication have been deposited in NCBI’s
Gene Expression Omnibus [4] and are accessible through
GEO Series accession number GSE88721 (https://
www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE88721).
Confirmation of microarray data with real-time PCR in pa-
tient samples
The levels of selected mRNAs and miRNAs in fifty-eight
patient samples, were checked. Among the miRNAs,
hsa-miR-8089 could not be detected in any of the sam-
ples potentially due to a problem in primer design. Al-
though the microarray result suggested that miR-4492-
3p levels are higher in meningioma samples than in the
healthy control, we have observed the opposite with
real-time PCR (Fig. 1). The level of miR-29c-3p in pa-
tient samples and healthy controls was consistent with
the microarray (Fig. 1).
RPL22, CABIN1, and RELA levels were not signifi-
cantly different from the controls (Fig. 1) whereas PTX3,
SPARCL1, and TMOD1 levels were in synchrony with
the microarray results. These are significant as PTX3
was downregulated and SPARCL1 and TMOD1 were
upregulated in patient samples compared with controls.
Anti-miR mimics successfully transfected into cell lines
We assessed the transfection capability of the X-
tremeGENE siRNA Transfection Reagent, and the ability
of the anti-miR mimics to suppress their target miRNAs
in two primary patient-derived meningioma cells. We
used Cy3 Labeled Pre-miR Negative Control #1 (Ther-
moFisher, AM17011) to visualize the presence of anti-
miRNA mimic molecules inside the cell 8 h after trans-
fection. Fluorescence microscopy showed that the Cy3-
labeled miRNA constructs were successfully transfected
into cells (Fig. 2a,b). No fluorescence was detected in
the control groups (Fig. 2c,d). Anti-miR mimics were
transfected into patient-derived cell lines, and real-time
PCR after 48 h revealed that the corresponding anti-miR
mimics significantly decreased the level of hsa-miR-29c-
3p and hsa-miR-4492-3p (Fig. 2e,f ). Levels of hsa-miR-
8089 could not be detected.
Table 1 Number and significance range of molecules
participating in relevant pathways and molecular and cellular
functions in meningioma. Table derived from data compiled
from DAVID bioinformatics database. P values were calculated
with a right-tailed Fisher’s exact test
Gene Network p-value Number of Molecules
Involved
Inflammatory Response 1.35E-03 – 8.27E-14 182
Cancer 1.28E-03 – 3.20E-11 493
Inflammatory Disease 1.35E-03 – 2.98E-10 161
Cellular Growth 1.23E-03 – 5.70E-18 311
Cell Death-Cell Survival 1.30E-03 – 7.59E-16 265
Cellular Movement 1.34E-03 – 6.11E-15 194
Cellular Development 1.04E-03 – 2.68E-13 257
Cell-Cell Signalling 1.34E-03 – 6.69E-10 157
Immune Cell Traficking 1.06E-03 – 1.95E-09 110
Table 2 Selected mRNAs and miRNAs as a result of microarray
analysis. Fold change, the matching miRNA for targeting, fold
value of miRNA, and information about targeting has already
been validated or predicted with software
mRNA Fold Targeting miRNA miRNA Fold Targeting Status
PTX3 -337.5 hsa-miR-29c-3p 21.76 Predicted
RPL22 -109.5 hsa-miR-29c-3p 21.76 Validated
CABIN1 -8.76 hsa-miR-4492 53.89 Predicted
RELA -7.42 hsa-miR-8089 22.13 Predicted
SPARCL1 71.88 N/A
TMOD1 81.71 N/A
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Fig. 1 The relative expression levels of selected mRNAs and miRNAs in patient samples as determined by real-time PCR analysis. Each point
represents a patient sample or healthy control cell line. P values are indicated on each graph
Fig. 2 Confirmation of miRNA transfection and anti-miR functionality. Cy3-conjugated scrambled anti-miRNA molecules were transfected into (a)
MEN-117, (b) MEN-117 negative control, (c) MEN-141, and (d) MEN-141 negative control for direct observation of cellular uptake. Observation was
made 8 h after transfection. The red spots represent Cy3-labeled anti-miRNA molecules and the nucleus is stained with DAPI (blue). No Cy3
labeled anti-miRNA mimics were transfected to negative controls but only DAPI. Scale bars indicate 12 μm length. Anti-miRNA molecules were
transfected into MEN-117 and MEN-141 cells. The ability of anti-miRNA molecules to decrease corresponding miRNA levels: (e) The decreased
level of miR-29c-3p by anti-miR-29c-3p. f The decreased level of miR-4492 by anti-miR-4492. *p < 0.05; **p < 0.01
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Transfection of anti-hsa-miR-29c-3p increased
oncosuppressor PTX3
The expression level of validated target RPL22 and pre-
dicted target PTX3 was checked 48 h after anti-miR-
29c-3p transfection. We did not observe a significant
effect on the RPL22 level compared to the control (Fig.
3a). The PTX3 gene expression level increased signifi-
cantly in primary cell lines MEN-117 and MEN-141,
suggesting a regulation of the gene by miR-29c-3p in
meningiomas (Fig. 3b). The expression level of the pre-
dicted target of hsa-miR-4492, CABIN1, increased both
in MEN-141 and MEN-117 cells (Fig. 3c). Although re-
sults for miR-8089 expression level confirmation with
real-time PCR could not be obtained we decided to carry
on with experiments that are not related to measuring
the expression level of the miRNA. The level of RELA
consistently increased in both MEN-117 and MEN-141
upon transfection with anti-miR-8089 (Fig. 3d).
Downregulation of hsa-miR-29c-3p decreased cell viability
and induced apoptosis in meningioma Cells
To observe the viability and percentage of apoptotic
cells, anti-miR molecules against miR-29c-3p were trans-
fected into two meningioma primary culture cells,
MEN-117 and MEN-141. MTS cell viability analysis re-
sulted in the decrease of viability of anti-miR-29c trans-
fected cells as compared to controls at day 3. This effect
was neutralized at day 4 (Fig. 4a,b).
For flow cytometry analysis, the population for apop-
totic cells was chosen as the annexin V-positive and
7AAD- negative cells to eliminate any confusion of late
apoptotic and necrotic cells, which are positive for
annexin V and 7AAD. The results showed that the anti-
miR-29c-3p molecules significantly increased apoptosis
after 72 h by 10% in MEN-117 and by 28% in MEN-141
when compared with the anti-scr control (Fig. 4c,d).
Correlation between the level of dysregulated miRNAs
and mRNAs with clinicopathological features of
meningioma patients
We evaluated the relationships between miR-29c-3p,
miR-4492, PTX3, RPL22, CABIN1, RELA, SPARCL1,
and TMOD1 levels and the clinicopathological features
of meningioma patients including sex, age, tumor grade,
tumor volume, calcification, progesterone receptor sta-
tus, and p53 and Ki67 levels, as well as the correlation
between the level of miRNAs and their targets. miR-
8089 was excluded since its level of expression could not
be determined by real-time PCR. For the chi-square
tests, patients were separated into two groups of low
and high levels of the corresponding miRNA or mRNA
level.
Among the clinical characteristics evaluated, miR-29c-
3p was negatively correlated with Ki67 index. PTX3,
RPL22, CABIN1 and SPARCL1 expression was nega-
tively correlated with progesterone receptor. RELA and
TMOD1 were negatively correlated with calcification
(Table 3). PTX3 and RELA were negatively correlated
with tumor volume in our cohort (Fig. 5).
Discussion
Since the genomic revolution began, our knowledge
about cancers has rapidly improved, leading to the dis-
covery of molecular markers that predict outcomes and
Fig. 3 Target mRNA expression levels after administration of corresponding anti-miRNA molecules. Anti-miRNA molecules of miRNAs, miR-29c-3p,
miR-4492, and miR-8089, were administered to MEN-117 and MEN-141, and corresponding target mRNA levels were determined after 48 h. a
RPL22 as the target of miR-29c-3p. b PTX3 as the target of miR-29c-3p. c CABIN1 as the target of miR-4492. d RELA as the target of miR-8089.
*Significant changes (p < 0.05)
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help define the best choice for treatment. In the near fu-
ture, molecular classification and, consequently, person-
alized therapy is the ultimate goal of treatment for any
tumor. Studies using microarray analysis can reveal gene
networks that relate to treatment response, clinical out-
come, and clinical progression.
Fifteen different subtypes of meningioma have been
identified by the World Health Organization (WHO).
These subtypes are further classified into three categor-
ies: benign (80%), atypical (15%–20%), and malignant
(1%–3%) [5]. An atypical meningioma is diagnosed by
observing necrosis, sheeting, prominent nucleoli, cellu-
larity, and cell size along with the recent criterion of
brain invasion [6].
MicroRNAs (miRNAs) are small, non-coding RNA
molecules that are about 22 nucleotides long. There is
growing interest in miRNAs with respect to their role in
the initiation and progression of cancer, but studies of
the miRNA profile of meningiomas are limited in num-
ber. In one study, 60 sporadic meningiomas and three
healthy arachnoidal tissue samples were used in a whole
genome array to find that miR-200a down regulation
was associated with tumor growth, epithelial-to-
mesenchymal transition status, and Wnt signaling [7].
miR-145, which decreased proliferation and induced
apoptosis in vitro and in vivo, was downregulated in
atypical and anaplastic meningiomas when compared
with benign meningiomas and this molecule [8].
Previous studies using microarrays led to the discovery
of important dysregulated mRNA molecules and altered
pathways, such as IGF2, Wnt, PI3K, MAPK, MMP12,
and TGF-β [9–12]. But few studies of the miRNA profil-
ing of meningiomas have been conducted. A number of
miRNAs have been found to be dysregulated. These in-
clude miR-145, let-7d, miR-335, miR-98, miR-181a, miR-
200a, miR-373*, miR-575, miR-335, miR-96-5p, miR-
190a, miR-29c-3p, and miR-219-5p [7, 8, 13, 14]. But
only two of these studies incorporated microarray data.
In addition, no common miRNA has been identified in
any two of these studies, reflecting the lack of well-
designed studies in this field of research.
Our microarray data defined three miRNAs that can
play a role in gene networks and that are potentially im-
portant for meningioma initiation and progression. To
the best of our knowledge, there is no previous inte-
grated miRNA-mRNA study of meningiomas that uses
Fig. 4 miR-29c-3p has an anti-proliferative and apoptotic effect on meningioma cells. Anti-scr transfected cells were used as the control groups
(a, b), and viability was measured with an MTS assay after transfection of miR-29c-3p into meningeal cells for 72 and 96 h. c Early apoptosis
(annexin V + 7-AAD) rate after transfection of miR-29c-3p into meningeal cells for 72 h. d Representative images of Annexin-V/7-AAD staining of
meningeal cells after miR-29c-3p transfection for 72 h
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microarray data. In addition, ours is the first study in
which a miRNA and mRNA expression profiles have
been observed in the same samples. Combining the data
from the two most up-to-date arrays provided us with
valuable information on potential gene networks in the
disease about inflammatory responses, cancer, cellular
growth and survival, cellular movement and develop-
ment, cell-to-cell signaling and immune cell trafficking.
A limitation to our study is the usage of one healthy hu-
man cell line due to unavailability of more commercial
cell lines and ethical difficulty in acquiring healthy men-
ingeal tissue from patients du to ethical responsibilities.
In further studies the number of healthy controls should
be increased and should not be limited to only cell lines
but also healthy meningeal tissue.
In this study, we found that miR-29c-3p is upregulated
in meningiomas, whereas its predicted target PTX3 is
downregulated. Inhibiting miR-29c-3p has increased the
expression level of PTX3 in primary meningioma cells,
indicating a potential targeting of PTX3 by miR-29c.
Table 3 Correlation between the expression level of selected miRNAs and mRNAs with clinicopathological features. Selected
miRNAs and mRNAs were analyzed with Spearman’s non-parametric correlation test and the chi-square test for age, sex, WHO grade,
calcification, progesterone receptor status, p53 status, and Ki67 index. Significant results are shown here
Molecule Name Clinicopathological Features High Low Total p-Value
miR-29c-3p Ki67 index
>7 12 19 31 0.0471
≤7 17 10 27
PTX3 Progesterone Receptor
Positive 16 25 41 0.0002
Negative/Focal Positive/Nuclear Positive 11 0 11
RPL22 Progesterone Receptor
Positive 19 22 41 0.0361
Negative/Focal Positive/Nuclear Positive 9 2 11
CABIN1 Progesterone Receptor
Positive 14 27 41 0.0004
Negative/Focal Positive/Nuclear Positive 10 1 11
SPARCL1 Progesterone Receptor
Positive 16 25 41 0.0022
Negative/Focal Positive/Nuclear Positive 10 1 11
RELA Calcification
Positive 17 25 42 0.0447
Negative 10 4 14
TMOD1 Calcification
Positive 17 25 42 0.0447
Negative 10 4 14
Fig. 5 Correlation between the expression level of selected PTX3 and RELA with tumor volume. Selected miRNAs and mRNAs were analyzed with
Spearman’s non-parametric correlation test for tumor volume. Significant results are shown here. PTX3 and RELA expressions are indicative of
lower tumor volume in the meningioma cohort
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miR-29c-3p was found to be downregulated when com-
pared with adjacent tissue in meningioma. In the same
study, lower miR-29c was associated with advanced clin-
ical stages of meningioma which is in synchrony with
our finding that lower miR-29c is associated with a
higher ki67 index [14]. The miR-29 family members
miR-29a, miR-29b, and miR-29c have diverse roles in
cancer [15] by inhibiting tumorigenesis [16], promoting
cancer cell apoptosis [17], and suppressing cell prolifera-
tion [18]. On the other hand, the miR-29 family can in-
duce an epithelial-to-mesenchymal transition acting as
drivers of tumor growth and metastasis [19]. In our
study, the downregulation of miR-29c decreased cell via-
bility and increased apoptosis.
PTX3 plays a role in inflammation, both endogenously
and exogenously, with dual effects on the process [20,
21]. PTX3 is considered a tumor suppressor gene that
plays a role in tumor-promoting inflammation in cancer
[22]. Our data show that the tumor suppressor PTX3 is
constitutively downregulated in meningiomas. PTX3
level was negatively correlated with tumor volume and
progesterone receptor level in our cohort which sup-
ports the argument that the gene can act as a tumor
suppressor for meningioma. Progesterone level relates to
the WHO grade and Ki67 status of meningiomas, as
previously reported [23]. Furthermore, our microarray
data show the altered expression of hundreds of mole-
cules that take part in inflammatory pathways. These
findings suggest that the emerging cancer hallmark of
tumor-promoting inflammation is potentially a driving
force in the initiation and progression of meningiomas
with PTX3 potentially taking part in the process.
We also assessed relationship between the selected
miRNAs and mRNAs and clinicopathological features.
High TMOD1 and RELA levels were associated with low
calcification in our patient group. Calcification is consid-
ered predictive of outcome in meningioma patients. The
level of calcification in tumors seen on magnetic reson-
ance images is used to determine the treatment strategy
for the tumor. Calcification in meningiomas is associated
with a low growth rate, suggesting a conservative treat-
ment option [24]. RELA level is also associated with a
lower tumor volume in our cohort. RPL22, CABIN1 and
SPARCL1 levels were also negatively correlated with the
progesterone receptor level, a relation similar to that of
PTX3.
The level of miR-4492 was found to be upregulated in
our microarray data. However real-time PCR confirm-
ation tests revealed that this miRNAs was significantly
downregulated not only in the group that microarray
analysis was conducted but also in our extended cohort.
This is probably due to an error in the microarray design
for the particular miRNA which is relatively recently dis-
covered. This result shows that microarray assessments
may not always be indicative of the level of expression
and confirmation with real-time PCR is crucial to detect
the expression level.
Conclusions
Our study presents valuable integrated data about
mRNA and miRNA expression in meningioma samples.
Markers that can play a role in meningioma pathophysi-
ology and tumor-promoting inflammation have been de-
termined, and the results reveal that the relationship
between miR-29c-3p and PTX3 can be one of the driv-
ing forces in meningioma pathology. Further studies of
these gene networks can produce translational informa-
tion, leading to a better understanding of the initiation
and progression of meningiomas and perhaps introdu-
cing alternative treatment approaches for the disease.
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